Editas醫藥 EDIT 深 滬
已收盤 12-12 16:00:00 美东时间
2.53
-0.030
-1.17%
華盛通- 最 高2.60
- 今 開2.57
- 成交量 226.82万股
- 最 低 2.465
- 昨 收 2.56
- 總市值 2.12亿
- 52周最高 4.5372
- 市盈率 靜 --
- 換手率 2.71%
- 52周最低 0.9101
- 委 比 -88.00%
- 總股本 8371.29万
- 歷史最高 99.95
- 量 比 1.38
- 振 幅 5.27%
- 歷史最低 0.9101
- 每 手 1
- 風險率 0.80%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Editas Medicine Q3 EPS $(0.28) Beats $(0.29) Estimate, Sales $7.543M Beat $5.020M Estimate
Editas Medicine (NASDAQ:EDIT) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.29) by 5.08 percent. This is a 62.67 percent increase over losses of $(0.75) per share from
11-10 20:21
Editas Medicine Announces Third Quarter 2025 Results and Business Updates
<p>Editas Medicine reported progress on its lead in vivo therapy,EDIT-401, targeting LDL-C reduction, with preclinical data showing over 90% LDL-C reduction in non-human primates. The company plans to submit an IND/CTA by mid-2026 and achieve initial human proof-of-concept data by year-end 2026. The company extended its cash runway into the third quarter of 2027. Third-quarter financials showed a net loss of $25.1 million, with collaboration reve...
11-10 12:00
Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025
Editas Medicine to Present CRISPR Gene Editing for LDL Cholesterol Reduction at AHA 2025. The presentation will discuss a transformative CRISPR-based medicine to lower LDL cholesterol. Session details: November 8, 10:45 a.m. to 11:45 a.m. CT in the Basic Science Zone at the American Heart Association Scientific Sessions in New Orleans. Anshul Gupta, Vice President of Preclinical Development, will present. The abstract is available on the AHA webs...
11-03 14:00
Gene editing therapy companies rise on word of streamlined FDA approval process
Companies focused on gene editing therapies, including CRISPR Therapeutics (CRSP), Editas Medicines (EDIT), and Intellia Therapeutics (NTLA) are trading higher Friday following a report that the US FD...
11-01 00:14
Intellia Freezes Key Trial After Serious Liver Event, Stock Tumbles
Intellia Therapeutics (NASDAQ: NTLA) paused their Phase 3 MAGNITUDE and MAGNITUDE-2 trials after a serious liver-related adverse event.
10-27 22:38
快讯 | 美股基因编辑概念股盘前下挫，NTLA一度暴跌超60%
基因编辑公司 $Intellia Therapeutics (NTLA.US)$ 盘前一度暴跌超60%，消息面上，该公司宣布暂停其针对转甲状腺素蛋白淀粉样伴心肌...
10-27 20:17
HURRICANE ANNOUNCES MODEL REFRESH FOR SUNDECK 2690
ELKHART, Ind., Oct. 23, 2025 /PRNewswire/ -- Hurricane Boats, legendary innovator in versatile deck boat designs, announced today it has redesigned the classic, Yacht Series Hurricane SunDec...
10-24 00:17
FIRST CREDIT：请求复核GEM上市委员会的决定
FIRST CREDIT（08215）发布公告，根据GEM上市规则第四章，公司有权自发出除牌决定当日起七个营业日内（即2025年10月15日或之前）将除牌决定提...
10-23 08:20
深度｜诺奖背后生物技术公司力量迅速崛起，科学家创业有何秘诀？
在做科研的时候，一定是挑专业领域里最难的问题去攻克，而在创办企业的时候，应该要挑最容易的那部分去做，这样才最有可能将科研成果转化为实际的经济收益。 诺贝...
10-12 14:06
